Alzheimer’s Disease Cooperative Study, Biohaven Jointly Launch Clinical Trial for Trigriluzole

Alzheimer’s Disease Cooperative Study, Biohaven Jointly Launch Clinical Trial for Trigriluzole
Biohaven and the Alzheimer's Disease Cooperative Study (ADCS) have jointly launched a Phase 2 clinical trial for the investigational drug trigriluzole, a glutamate modulating candidate that could potentially improve symptoms in patients with mild to moderate Alzheimer's disease. Preclinical studies and post-mortem human Alzheimer's studies suggest that abnormalities in the signaling of the neurotransmitter glutamate — the brain's dominant fast-acting neurotransmitter — contribute to devastating diseases including ataxia, amyotrophic lateral sclerosis, Alzheimer's and other neurodegenerative disorders. Trigriluzole, which is being developed by Biohaven, was first tested as a potential treatment for ataxias. The randomized, double-blind, placebo-controlled Phase 2 clinical trial is being jointly sponsored by ADCS and Biohaven, based in New Haven, Connecticut. Supported by the U.S. National Institute on Aging — a division of the National Institutes of Health — the ADCS consortium promotes the discovery and testing of new Alzheimer's medicines. In that regard, ADCS has completed many Alzheimer's clinical trials. The consortium operates out of the University of California San Diego (UCSD) School of Medicine and has numerous clinical research sites at academic and private research centers in the United States and Canada. Biohaven and ADCS began collaborating six months ago. "We are excited to be working with the ADCS to evaluate trigriluzole in patients with AD and attempt to alleviate suffering from this devastating d
Subscribe or to access all post and page content.

One comment

  1. Molly Jones says:

    This is hard to follow: I thought Biohaven found a negative result for the trial “trigriluzole did not differentiate from placebo on primary endpoint or key secondary outcome” What is the difference here?

Leave a Comment

Your email address will not be published. Required fields are marked *